Page 172 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.1. Descriptive characteristics of the epidemiologic studies considered relevant to KQ1 (continued)
Author Database Start End year Sample size Eligibility criteria
Year year
uid
41
Miller SEER 1988 2002 71,602 Localized or regional adenocarcinoma of the prostate. Excluded men with
2006 [an additional missing information that precluded assigned to a risk group (based on age
16912266 historical cohort of and grade criteria) and those with missing information on primary treatment,
25,826 men race/ethnicity, or marital status.
diagnosed during
1988-90 was used
to compare
treatment patterns]
42
Shao SEER 1988 2005 82,541 Age ≥25 yr. Excluded men of race/ethnicity other than Black or White, those
2009 (2004-05) with missing data on age, PSA, Gleason score, or clinical stage
19713548 (NR for other yr)
82
Abdollah SEER 1988 2006 404,604 Histologically-confirmed nonmetastatic prostatic adenocarcinoma, managed
2011 with RT, RP or observation. Only included men with localized prostate cancer,
20965646 aged 30-95 yrs. Excluded individuals with unknown grade, or undifferentiated
disease.
43
Merrill SEER 1989 1993 80,936 White and Black prostate cancer patients.
1996 [72,659 White;
8931614 8277 Black]
44
Stewart SEER, NCHS 1990 2000 NR NR
2004
15179359
45
Zhu SEER 1990 2004 42,751 NR
2009 [The study reported additional data from ACTUR, a tumor registry for military
19505907 personnel; these data were not considered representative of the US
population and pertained to <1000 prostate cancer cases, thus they were not
extracted.]
46
Polednak SEER 1992 1998 46,248 Excluding cases ascertained from death certificate only or autopsy. Data only
2002 [in 1992: 2969 reported for non-Hispanic White and Black patients.
12477140 Black, 23,347 non-
Hispanic White; in
1997: 2821 Black,
17,111 non-Hispanic
White
83
Paltoo SEER 1992 1999 NR Any incident cancer. American Indian or Alaskan Native, or white.
2004
15219802

C-4